China's Biopharma Sector Expected to Receive More Government Support -- Market Talk

Dow Jones

03/18

0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.(jason.chau@wsj.com)

(END) Dow Jones Newswires

March 17, 2026 23:12 ET (03:12 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2620858872"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620858872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620858872?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620858872","market":"nz","top_or_hot":-1,"title":"China's Biopharma Sector Expected to Receive More Government Support -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and <a href=\"https://laohu8.com/S/00241\">Ali Health</a>.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 23:12 ET (03:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Biopharma Sector Expected to Receive More Government Support -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Biopharma Sector Expected to Receive More Government Support -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-18 11:12</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and <a href=\"https://laohu8.com/S/00241\">Ali Health</a>.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 23:12 ET (03:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0819121731.USD","symbol_name":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620858872","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620858872","pubTimestamp":1773803520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","03692":"翰森制药","BK1142":"互联网与直销零售","01801":"信达生物","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1576":"医药外包概念","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","LU0261945553.USD":"FIDELITY ASEAN \"A\" ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK1502":"双十一","BK1610":"ETF&股票定投概念","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","BK6523":"ESG概念","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU2152927971.USD":"NORDEA 1 ASIAN STARS EQUITY \"BP\" (USD) ACC","BK1615":"港股-互联网","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","SG9999002679.SGD":"LionGlobal Singapore Balanced SGD","00241":"阿里健康","LU0572940350.SGD":"Janus Henderson Horizon Asian Dividend Income A3 SGD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1515":"抗疫概念","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","SG9999013486.USD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (USD) INC A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK0216":"研究试验","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0210637038.USD":"HSBC GIF THAI EQUITY \"AD\" INC","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","02269":"药明生物","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC"},"translate_title":"中国生物制药行业有望获得更多政府支持——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"00241":0.9,"03692":0.9,"01801":0.9,"02269":0.9},"content_text":"0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.(jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 23:12 ET (03:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}